Glaucoma "the silent thief of sight" - PowerPoint PPT Presentation

About This Presentation
Title:

Glaucoma "the silent thief of sight"

Description:

Glaucoma management and challenges – PowerPoint PPT presentation

Number of Views:708
Slides: 45
Provided by: abduulwahab
Category:
Tags: glaucoma

less

Transcript and Presenter's Notes

Title: Glaucoma "the silent thief of sight"


1
(No Transcript)
2
NANNM CONTINUING EDUCATION COMMITTEE FEDERAL
TEACHING HOSPITAL GOMBE
  • TOPIC GLAUCOMA THE SILENT THIEF OF SIGHT.
  • PRESENTER ABDULWAHAB USMAN (NOI)
  • DATE12 TH APRIL,2016
  • VENUE CONFERENCE HALL FTH GOMBE

3
OUTLINE
  • INTRODUCTION
  • DEFINITION
  • BRIEF ANATOMY AND PHYSIOLOGY
  • CLASSIFICATION
  • MANAGEMENT
  • NURSING CARE
  • CHALLENGES
  • RECOMMENDATIONS
  • CONCLUSION
  • REFERENCES

4
INTRODUCTION
  • Glaucoma is considered to be the second largest
    cause of blindness after cataract worldwide, and
    the foremost cause of irreversible blindness.
  • In 2013, the number of people with glaucoma
    worldwide was estimated to be 64.3 million ,
    increasing to 76.0 million in 2020 and 111.8
    million in 2040.
  • Glaucoma is mostly refer to as the silent thief
    of sight due to its asymptomatic nature at early
    stage.
  • Early detection and effective treatment are
    necessary to prevent loss of vision.

5
DEFINITION
  • Glaucoma is a group of ocular disease
    characterized by progressive optic neuropathy
    resulting in optic disc defect and irreversible
    visual field loss that are usually associated
    with raised intraocular pressure.

6
BRIEF ANATOMY PHYSIOLOGY
7
PRODUCTION AND FLOW OF AQUEOUS HUMOUR
  • Aqueous humour, derived from plasma, is produced
    from ciliary process. From there, it passes to
    posterior chamber and then around iris to
    anterior chamber. From the anterior chamber, it
    either drains into schlemn's canal via trabecular
    meshwork Trabecular outflow or goes back into
    ciliary process towards venous circulation
    Uveoscleral outflow.

8
(No Transcript)
9
(No Transcript)
10
CLASSIFICATION
  • Congenital /developmental Glaucoma
  • Primary
  • Secondary

11
CONGENITAL GLAUCOMA
  • Congenital glaucoma is further classified as
    follows depending on the age of onset.
  • True congenital glaucoma (40)
  • Infantile glaucoma (55)
  • Juvenile glaucoma (5)
  • It affects 1 in 10,000 birth of the population .
  • 70 bilateral.

12
(No Transcript)
13
CLINICAL FEATURES
  • Corneal oedema
  • Lacrimation , photophobia and blepharospasm
    (Classic Triad).
  • Corneal enlargement.
  • Haabs striae.
  • Raised IOP

14
(No Transcript)
15
EVALUATION
  • Tonometry
  • Measurement of corneal diameter by callipers
  • Slit lamp examination
  • Ophthalmoscopy
  • Gonioscopy

16
MANAGEMENT
  • Primarily surgical.
  • Goniotomy.
  • Trabeculotomy if goniotomy fails or when the
    corneal clouding prevent visualisation of the
    angles.
  • Trabeculectomy.

17
PRIMARY GLAUCOMA
  • Primary open angle glaucoma (POAG)
  • Primary angle closure glaucoma (PACG)
  • PRIMARY OPEN ANGLE GLAUCOMA
  • Adult onset
  • An open angle of normal appearance.
  • Most prevalent type of Glaucoma (1/3)
  • 1 in 100 0f the population gt 40 years.

18
RISK FACTORS
  • Age gt 40 years
  • Race develop earlier and more severe in black
    than white
  • Family history
  • Diabetes and Hypertension
  • Myopes
  • Low CCT lt 555um
  • Retinal diseases
  • Steroids

19
CLINICAL FEATURES
  • Asymptomatic at early stage
  • Headache
  • Eye ache
  • Scotoma
  • Difficulty in reading and close work
  • Delayed dark adaptation
  • Decrease visual acuity
  • Increase IOP
  • Cupping of the optic disc

20
(No Transcript)
21
(No Transcript)
22
(No Transcript)
23
EVALUATION
  • Visual acuity
  • Slit lamp examination
  • Tonometry
  • Pachymetry
  • Perimetry
  • Ophthalmoscopy
  • Gonioscopy

24
(No Transcript)
25
(No Transcript)
26
MANAGEMENT
  • Initial therapy is medical , with surgery as the
    last resort.
  • Beta blockers eg Timolol maleate and Betaxolol
  • Prostaglandin analogue eg Latanoprost.
  • Adrenergic drugs eg Brimonidine
  • Carbonic anhydrase inhibitors eg Dorzolamide and
    Acetazolamide
  • Miotics eg pilocarpine
  • Hyperosmotic agent eg mannitol
  • SURGERY
  • Laser trabeculoplasty
  • Trabeculectomy

27
NORMAL TENSION GLAUCOMA
  • Also called low tension glaucoma, is when typical
    glaucomatous changes and visual field defects are
    associated with an IOP that is constantly below
    21mmHg
  • It is believed to result from low vascular
    perfusion which makes the optic nerve head more
    susceptible to normal IOP.
  • Betaxolol is the drug of choice

28
OCULAR HYPERTENSION
  • Also called glaucoma suspect is when a patient
    has an IOP constantly more than 21mmHg but no
    optic disc and visual field defects.
  • The patient should be carefully monitored and
    should be treated as a case of POAG in the
    presence of risk factors.
  • Significant diurnal variation of more than 8mmHg
    between the lowest and the highest values of IOP
  • IOP constantly more than 28mmHg
  • Significant asymmetry in the cup size of the two
    eyes i.e gt 0.2.

29
PRIMARY ANGLE CLOSURE GLAUCOMA
  • Primary angle closure disease is characterized by
    apposition of the peripheral iris against the
    trabecular meshwork, resulting in obstruction of
    the aqueous outflow.
  • Primary angle closure glaucoma is used only when
    the optic disc and visual field changes are
    present.

30
RISK FACTORS
  • Sex More in female than male. 41.
  • Hereditary
  • Age More in advance age with highest frequency
    in 6th and 7th decades.
  • Hypermetropics due to shallow anterior chamber
    and short axial length.
  • Race More in South East Asians, Chinese and
    Eskimos than blacks.

31
CLINICAL FEATURES
  • Severe pain
  • Nausea , vomiting and prostration
  • Red eye
  • Photophobia
  • Lacrimation
  • Raised IOP (40-70mmHg)
  • Ocular structures becomes oedematous
  • Closed angle of anterior chamber
  • Fixed and dilated pupils

32
(No Transcript)
33
MANAGEMENT
  • Primary angle closure disease is a serious
    ophthalmic emergency and needs to be manage
    aggressively as follows
  • Immediate medical therapy to lower IOP
  • Systemic hyperosmotic agents e.g Mannitol and
    Glycerol
  • Systemic CAI e.g Acetazolamide 500mg t.d.s
  • Topical anti-glaucoma drugs beta blockers and
    prostaglandin analogues.
  • Analgesia
  • Antiemetic
  • Antinflammatory

34
  • Definitive therapy
  • Surgeries i.e laser peripheral iridotomy, laser
    iridotomy and trabeculectomy
  • iii. Prophylaxis of the fellow eye
  • Prophylaxis surgery should be performed on the
    fellow asymptomatic eye as early as possible as
    chances of acute attack is 50 in such eye.
  • iv. Long term glaucoma surveillance and IOP
    management in both eyes.

35
SECONDARY GLAUCOMAS
  • Depending on the cause, secondary glaucoma are
    named as follows
  • Lens induced glaucoma
  • Inflammatory glaucoma
  • Neovascular glaucoma
  • Glaucoma associated with intraocular haemorrhage
  • Glaucoma associated with intraocular tumor
  • Steroid induced glaucoma
  • Traumatic glaucoma
  • Glaucoma in aphakia
  • Pseudoexfoliative glaucoma
  • Pigmentary glaucoma

36
NURSING CARE PLAN FOR A GLAUCOMA PATIENT
NURSING DIAGNOSIS NURSING OBJECTIVE NURSING INTERVENTION SCIENTIFIC RATIONALE EVALUATION
Disturbed visual sensory perception related to altered sensory reception as evidenced by loss of visual field/decreases visual acuity To maintain current visual field/acuity without further loss Determine type and degree of visual field loss Allow expression of feelings about loss and possibility of loss of vision Administer prescribed medications as indicated Prepare patient for surgery and care post operatively Baseline for evaluation Help reassure the patiient that vision loss cannot be restored but further loss can be prevented Control IOP and prevent further loss of vision To prevent further loss of vision Patient visual field /acuity was maintained without further loss
37
NURSING DIAGNOSIS NURSING OBJECTIVE NURSING INTERVENTION SCIENTIFIC RATIONALE EVALUATION
Anxiety(actual) related to loss of vision as evidenced by negative self-talk Allay anxiety Determine level of anxiety Give accurate and honest information Encourage patient to express feelings and concerns. Identify helpful resources and people Baseline for evaluation Lessens anxiety related to unknown. Provide opportunity for patient to deal with reality of situation and clarify misconceptions. Provide reassurance that patient is not alone in dealing with problem Patient anxiety was allayed
38
NURSING DIAGNOSIS NURSING OBJECTIVE NURSING INTERVENTION SCIENTIFIC RATIONALE EVALUATION
Knowledge deficit regarding disease process Patient will understand pathology and treatment of glaucoma Review pathology and lifelong need for treatment Demonstrate proper technique for administration of eye drops Discuss dietary consideration (adequate fluid and fiber intake) Identify potential side effects of treatment Provides opportunity to clarify and dispel misconception Enhance effectiveness of treatment To prevent constipation and straining during defecation May require medical evaluation and possible change in therapeutic regimen Patient understood pathology and treatment of Glaucoma
39
CHALLENGES
  • Late presentation
  • Lack of awareness
  • Delay in referral
  • Lack of expertise
  • Poor compliance with medical treatment
  • Lack of equipments
  • High cost of drugs
  • Fake drugs
  • Surgeons reluctance to offer surgery

40
RECOMMENDATIONS
  • Routine glaucoma screening to help detect the
    disease at early stage and prevent further loss
    of vision.
  • Increase awareness through health talk and media.
  • Early referral of patient from other health
    professionals to ophthalmic specialist.
  • Training and re-training of eye care personnel.
  • Provision of necessary equipments and proper
    maintenance of the little available ones.

41
  • Strict enforcement of regulation and supervision
    to curtail the circulation of fake drugs.
  • Patient education on the need for strict
    compliance with treatment regimen.
  • Government should subsidies the cost of glaucoma
    drugs.

42
CONCLUSION
  • Glaucoma represents a major public
  • health burden and even though the challenges of
  • management in developing countries are many, they
  • are not insurmountable. There is need for
    concerted
  • and integrated efforts involving all cadres of
    eye care
  • practitioners, patients, institutions and
    governments to address this important eye disease.

43
THANK YOU FOR LISTENING!
44
REFERENCES
  • http//www.cehjournal.org/category/glaucoma/
  • http//nurseslabs.com/3-glaucoma-nursing-care-plan
    s/
  • http//nursingcrib.com/nursing-notes-reviewer/medi
    cal-surgical-nursing/glaucoma/
  • http//eyewiki.aao.org/Glaucoma_in_the_Developing_
    World
  • http//www.cehjournal.org/article/visual-field-tes
    ting-for glaucoma-a-practical-guide/
  • http//www.cehjournal.org/article/the-optic-nerve-
    head-in-glaucoma/?utm_sourcehootsuite
  • http//www.nursingtimes.net/roles/older-people-nur
    ses/glaucoma-the-silent-thief-of-sight/5075669.ful
    larticle
  • http//nursingcrib.com/nursing-notes-reviewer/medi
    cal-surgical-nursing/glaucoma/
Write a Comment
User Comments (0)
About PowerShow.com